VX-407 Drug Interaction Study with Oral Contraceptives

Phase 1, open-label trial of VX-407 in autosomal dominant polycystic kidney disease (ADPKD) (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration of Oral Contraceptives and Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity of Oral Contraceptives. Started Sep 2026; status: recruiting.